ANORO ELLIPTA

Peak

umeclidinium bromide and vilanterol trifenatate

GSK
NDAINHALATIONPOWDER
Approved
Dec 2013
Lifecycle
Peak
Competitive Pressure
8/100

Mechanism of Action

vilanterol. The mechanisms of action described below for the individual components apply to Umeclidinium and Vilanterol ELLIPTA. These drugs represent 2 different classes of medications (an anticholinergic and a LABA) each having different effects on clinical and physiological indices. Umeclidinium…

Indications (3)

COPDasthmachronic obstructive pulmonary disease

Loss of Exclusivity

LOE Date
Nov 29, 2030
57 months away
Patent Expiry
Nov 29, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
8511304
Jun 14, 2027
Product
U-1476
8511304*PED
Dec 14, 2027
—
7488827
Dec 18, 2027
SubstanceProduct
—
11090294
Nov 29, 2030
U-3203
12396986
Nov 29, 2030
Product
—
Company
GSK
GSK
LONDON, United Kingdom
698 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers